Navigation Links
VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
Date:2/11/2008

term objectives,

including preparation for the start of Phase 2 clinical trials for its

lead product RAV12 as well as the advancement of two IND candidates.

-- The Companies have established transition and integration plans and

teams as they relate to information technology, human resource

policies, financial systems and reporting and Sarbanes-Oxley

compliance.

-- A number of VaxGen scientists are now working on Raven projects under

arms-length contractual arrangements. These arrangements serve to

advance critical R&D projects and are expected to facilitate the post-

close integration process.

-- The companies have determined that dedicating the use of the VaxGen

manufacturing facility to the Raven pipeline over the next two to

three years is not the most economically attractive option, and

therefore divestment or partnering of the facility is being actively

pursued.

"Our goal for the merged company is to focus on advancing our pipeline of monoclonal antibodies directed against cancer stem cells, and these actions will allow us to do this in what we believe will be the most cost-effective manner possible," said George F. Schreiner, M.D., Ph.D., Raven's Chief Executive Officer. "We are confident that this merger will provide value to investors and, subject to a positive stockholder vote and satisfaction of the closing conditions, we look forward to combining our two companies."

About VaxGen

VaxGen is a biopharmaceutical company based in South San Francisco, California. The company owns a state-of-the-art biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that can be used to make cell culture or microbial biologic products. For more information, please visit the company's web site at http://www.vaxgen.com.

About Raven

Rave
'/>"/>

SOURCE VaxGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
3. VaxGen Files First Quarter 2007 Financials
4. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
5. VaxGen Files Last Outstanding Periodic Report With SEC
6. VaxGen Addresses MPM Claims in Letter to Stockholders
7. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
8. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
9. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
10. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
11. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... SHANGHAI, June 29 /PRNewswire-Asia/ -- Sundia MediTech Company, ... Shanghai,China announced today that Dr. Tong Xu has been ... Prior to joining Sundia, Dr. Xu worked ... in San Diego, USA for 12 years. At ...
... Mylan Inc. (Nasdaq: MYL ) today ... with Biocon Limited, a publicly traded company on ... on the development, manufacturing, supply and commercialization of ... global marketplace. Through this partnership, Mylan and Biocon ...
... UPPSALA, Sweden, June 29 , ... Will Fund Gyros to Profitability , ... development, announces that it has raised SEK 80 million,(approximately euro ... Company,s leading shareholder. The new funds will enable Gyros to ...
Cached Biology Technology:Sundia MediTech Appoints Dr. Tong Xu as VP of Process Chemistry 2Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market 2Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market 3Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market 4Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 2Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 3Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 4
(Date:7/9/2014)... Jena (Germany) They are amongst the most numerous inhabitants ... Emiliania huxleyi . Not visible to the naked eye, ... square kilometer sized patches, they are even visible on ... is responsible for approximately half of the global ... Friedrich Schiller University Jena (Germany). In the process the ...
(Date:7/9/2014)... they are used in the right ways. ... Hospital and coauthors analyzed six use cases with ... decompensation (when a patient,s condition worsens); adverse events; ... organ systems. They suspect that cost-savings benefits will ... all six scenarios will be significant. The authors ...
(Date:7/8/2014)... LAKE CITY, July 9, 2014 Collectors found the first ... in west Texas. Then, for two decades, the 14-inch-tall plant ... a third. , Now after a long search turned ... Utah botanist and her colleagues identified the spiny plant as ... heart" in Latin because it was found in Valentine, Texas, ...
Breaking Biology News(10 mins):Short circuit in the food web 2The impact of big data on health care: Health Affairs' July issue 2New plant species from the heart of Texas 2New plant species from the heart of Texas 3New plant species from the heart of Texas 4New plant species from the heart of Texas 5
... Space is not a fun place to get a stomach ... Utah chemists developed a two-minute water quality monitoring method that ... Station. "Now they bring water back on the space ... there is a big delay. You,d like to be able ...
... difference can a tenth of a nanometer make? When it ... resolution of that miniscule amount can mean the difference between ... Case in point: New, improved-resolution views of a zinc transporter ... Laboratory provide not just a structure but also a suggested ...
... stamp that can sniff out poisonous gases or deadly toxins ... 13 issue of the journal Nature Chemistry , Kenneth ... developed an artificial nose for the general detection of toxic ... and works by visualizing odors. This sensor array could ...
Cached Biology News:Water quality in orbit 2Water quality in orbit 3Water quality in orbit 4High-res view of zinc transport protein 2High-res view of zinc transport protein 3Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3
...
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
... The NEW HandyStep electronic from BRAND ... pipetting. It is the only electronic, ... standard syringe tips, including BRAND PD-Tip ... Plus, Fisherbrand Dispenser Tips,and VWRbrand Combi-Syringes. ...
Biology Products: